Bernard-Soulier syndrome or idiopathic thrombocytopenic purpura: A case series

Abstract

Background: Bernard-Soulier syndrome (BSS) is a rare, autosomal recessive platelet function disorder which is commonly mistaken for idiopathic thrombocytopenic purpura (ITP). The report includes seven cases of BSS that have been diagnosed and treated as ITP for a long time.

Methods: Between 2006 and 2016, data of seven BSS patients who have long been diagnosed and treated as ITP were collected and analyzed.

Results: Two patients were males and 5 were females. The patient's age range was between one day and four years at the onset of symptoms. Easy bruising, nose bleeds and mucocutaneous bleeding were the most frequent symptoms. Bleeding attacks of the gum, gastrointestinal tract and menorrhagia also occurred and in one case bleeding in the injection site of the first vaccination was reported. In 6 patients, parents were relatives and in three cases, there was a family history of low platelet counts. Variable thrombocytopenia, prolonged bleeding time (BT), and large platelets with increased bone marrow megakaryocyte were seen in all cases. Most patients were treated with steroids, Intravenous immunoglobulin (IVIG), and some with IV anti-D, Azathioprine, Danazol, Rituximab. Spleenectomy was performed in one case. In supplementary tests the platelet aggregation to ristocetin was absent and GPIb expression level by flow cytometry method was lower than 10%.

Conclusion: BSS should always be considered in differential diagnosis of ITP especially in persistent and refractory ITP.

Keywords: Giant platelet, (GP) Ib/IX/V complex, Platelet function disorder, thrombocytopenia

Citation:
Reisi N. Bernard-Soulier syndrome or idiopathic thrombocytopenic purpura: A case series. Caspian J Intern Med 2020; 11(1):105-109.

Bernard-Soulier syndrome also known as Hemorrhagiparous thrombocytic dystrophy is a rare inherited bleeding disorder which affecting the megakaryocyte/platelet cell line, and first described in 1948 by Bernard and Soulier (1, 2). Quantitative or qualitative defect of platelet membrane glycoprotein (GP) Ib/IX/V complex, a receptor for von Willebrand factor (vWF) is the cause of disease (3, 4). It usually inherited in an autosomal recessive manner but there are families with dominant forms (3, 5). The incidence was reported less than 1:1000000 and in countries with high rate of consanguineous marriages it seems to be higher (6, 7, 8). Easy bruising, nosebleeds, gingival bleeding and menorrhagia are common clinical manifestations of the disease and severe life threatening bleeding is rare (3, 6, 9). Symptoms usually begin in early age (1, 8) but can unrecognized until the 3rd-4th decade (3). The severity and frequency of bleeding vary throughout life and diminish with age (1, 9) but menorrhagia and bleeding at the time of childbirth are problems for females (3, 10, 11). Thrombocytopenia, large platelet and prolonged bleeding time are its laboratory findings.
The diagnosis of BSS is usually based on absent response to ristocetin in platelet aggregation studies and low expression of platelet surface GPIb by flow cytometry. Molecular studies can also establish an abnormal genotype (1, 9, 12). Antifibrinolytic agents, desmopressin, platelet transfusion and recombinant factor VIIa are suggested treatments in this disease (13, 14).

This disease due to its clinical and laboratory manifestations has very close similarity with idiopathic thrombocytopenic purpura that is an acquired isolated immune thrombocytopenia. ITP is usually developed by the production of autoantibodies secondary to infections, vaccinations or drugs. Platelet surface receptor antibodies are detectable only in half of patients, and the diagnosis of ITP is one of exclusion. This disease is usually self-limited and observation is enough. Steroids, intravenous immunoglobulins (IVIG), anti-D globulin, and in chronic cases rituximab, thrombopoietin agonists and splenectomy are treatments (15). Glanzmann thrombasthenia, Von Willebrand disease, May-Hegglin anomaly and gray platelet syndrome are other differential diagnoses of BSS (1, 9). The objective of the present study is a reminder of this rare disease especially in differential diagnosis of unsuccessfully treated or refractory ITP.

Methods
In this study were collected clinical and laboratory data of 7 children less than 18 years at Seyed-al-Shohada Hospital in Isfahan, Iran since 2006 to 2016 which were diagnosed and treated as chronic ITP for a several years but due to lack of response to the treatment and clinical suspicion they were re-examined by supplementary tests and the BSS diagnosis is given to them. Demographic and general clinical data including age, sex, time of first bleeding, age of BSS diagnosis, type of bleeding signs and symptoms and family history of low platelet count, abnormal bleeding and consanguineous marriage were collected from patient files. The results of their laboratory findings included platelets count, mean platelet volume, presence of giant platelet in peripheral smear, IVY bleeding time and prothrombin time, level of fibrinogen, vWF antigen and vWF activity, FXIII screening, platelet function tests, bone marrow aspiration and biopsy and flow cytometry were recorded and analyzed.

Results
Demographic, clinical and laboratory findings and performed treatments in patients are summarized respectively, in table 1, 2 and 3. Two patients were males and 5 were females. The patient’s age range was between one day and four years at the onset of symptoms. Easy bruising, nosebleeds and mucocutaneous bleeding were the most frequent symptoms. Bleeding attacks of the gum, gastrointestinal tract and menorrhagia also occurred and in one case bleeding in the injection site of the first vaccination was reported. In six patients, parents were blood relative and in three cases, there was a family history of low platelet counts (table 1).

| Table1. Demographic and clinical data in seven BSS patients misdiagnosed as having chronic ITP |
| Variable                                                   | Case1 | Case2 | Case 3 | Case 4 | Case 5 | Case 6 | Case7 |
|------------------------------------------------------------|-------|-------|--------|--------|--------|--------|------|
| Age (yr)                                                   | 17    | 10    | 8      | 7      | 4      | 1.5    | 13   |
| Gender                                                    | female | male  | female | female | male  | female | female |
| Time of first bleeding (yr)                                | 3.5   | 3     | 2      | 4      | 2      | at birth | 4    |
| Family history of low platelet count± bleeding             | In uncle | -    | -      | In brother | In cousinry | -    | -    |
| Consanguineous marriage in parents                         | +     | +     | -      | +      | +      | +      | +    |
| Age of BSS diagnosis (yr)                                  | 15    | 7     | 7      | 5      | 3.5    | 1.2    | 13   |
| Easy bruising                                             | +     | +     | +      | +      | +      | +      | +    |
| Epistaxis                                                 | +     | +     | +      | -      | -      | -      | +    |
| Gingival bleeding                                         | -     | -     | +      | -      | -      | -      | -    |
| Gastrointestinal bleeding                                  | -     | -     | +      | -      | -      | -      | -    |
| Menorrhagia                                               | +     | -     | -      | -      | -      | -      | +    |
| Prolonged bleeding after vaccination, teething or surgery  | -     | -     | -      | -      | -      | -      | After first vaccination |

www.SID.ir
Variable thrombocytopenia, prolonged bleeding time (BT), and large platelets with increased bone marrow megakaryocyte were present in all cases. In supplementary tests the platelet aggregation to ristocetin was absent and GPIb expression level was lower than 10% of control values (table 2). Most patients were treated with steroids, intravenous immunoglobulin (IVIG), and some with IV anti-D, azathioprine, danazol, rituximab and splenectomy was performed in one case (Table 3).

Table 2. Laboratory analysis results in seven BSS patients misdiagnosed as having chronic ITP

| Criteria                      | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | Normal values (As per reference interval) |
|-------------------------------|--------|--------|--------|--------|--------|--------|--------|------------------------------------------|
| Hemoglobin level (gr/dl)      | 12     | 11.6   | 10.7   | 11.5   | 11     | 12     | 11     | 11.5 – 14.5                               |
| Platelets range (10^3/mm³)    | 45-100 | 43-90  | 30-104 | 70-104 | 42     | 61     | 45-60  | 150 - 450                                 |
| Mean platelet volume (fl)     | 10.5   | 12.3   | 10.1   | 10.5   | 11.8   | 11.4   | 10.3   | 7 - 9                                     |
| Giant platelet in peripheral smear | a lot | moderate | few | few | moderate | moderate | few | few |
| IVY bleeding time (min)       | 9      | 12     | 13     | 10     | 11     | 15     | 9.5    | 3 - 7                                     |
| Prothrombin time (sec)        | 13     | 10     | 10     | 11     | 10     | 11     | 13     | 10 - 13                                   |
| Activated partial thromboplastin time (sec) | 35 | 28     | 28     | 31     | 33     | 37     | 35     | 28 - 38                                   |
| Factor XIII screen (min)      | Normal | Normal | Normal | Normal | Normal | Normal | Normal | 30 - 240                                  |
| Fibrinogen* (gr/dl)           | 2.54   | 1.78   | 2.61   | 1.78   | 2.46   | 1.93   | 2.35   | 1.5 – 4.5                                 |
| vWF Antigen (Turbidimetric method) | 147  | 88     | 123    | 101    | 78     | 90     | 85     | 50 – 150%                                 |
| vWF Activity (RcCoF method)   | 121    | 96     | 109    | 87     | 95     | 88     | 94     | 50 – 150%                                 |
| F VIII Activity (1-Stage method) | 85  | 90     | 148    | 98     | 86     | 108    | 80     | 50 – 150%                                 |
| Bone marrow aspiration& biopsy| Normocellular marrow with trilineage hematopoiesis and increased megakaryocyte | | | | | | | |
| **Platelet aggregation**      | Absent response to ristocetin, aggregation with ADP, collagen and arachidonic acid |
| Platelet surface GPIb (CD42)  | 3.4%   | 4.2%   | 1.7%   | 5.1%   | 6.3%   | 2.3%   | 2.2%   | _                                          |

*(Claussmetod), **Platelet aggregation with: Ristocetin (0.75, 1, 1.25, 1.5 mg/ml), ADP (2*10^-5M, 4*10^-6M, 2*10^-6M), Collagen (200 micgrm/ml), Arachidonic acid (500 micgrm/ml)

Table 3. Performed treatments in seven BSS patients misdiagnosed as having chronic ITP

| Treatment                  | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 |
|----------------------------|--------|--------|--------|--------|--------|--------|--------|
| Prednisone                 | +      | +      | +      | +      | +      | -      | +      |
| Intravenous immunoglobulin (IVIG) | +    | +      | +      | -      | -      | -      | +      |
| Anti Rh(D) immunoglobulin (IV anti-D) | -  | +      | -      | -      | -      | -      | -      |
| Azathioprine               | +      | +      | +      | -      | -      | -      | -      |
| Danazol                    | +      | -      | -      | -      | -      | -      | -      |
| Rituximab                  | -      | +      | +      | -      | -      | -      | -      |
| Splenectomy                | +      | -      | -      | -      | -      | -      | -      |

Discussion

In present study we reported seven patients with Bernard-Soulier syndrome which had been treated and followed-up a long time as ITP, but due to the lack of response to ITP treatments and clinical suspicion, they were re-examined and finally platelet aggregation tests and flow cytometric studies disclose the diagnosis. BSS is a rare, genetically inherited bleeding disorder which is due to its rarity, less consider in patients with thrombocytopenia and often misdiagnosed with ITP (16, 17). There are clinical and laboratory clues that can
help differentiate these two: BSS is usually an autosomal recessive disorder, so it is more common in the countries with very high proportion of consanguineous marriages (18). Iran (3, 6), Pakistan and the Arab countries, are areas that are more likely to be affected (5). In report on the annual global survey 2017 of World Federation of Hemophilia that has reported 667 cases of BSS from 113 countries, Iran was at the top with 100 cases (18). Nowadays, the number of reported cases of countries with a lower percentage of consanguineous marriages like United Kingdom, Brazil and France are also high (18). The reason for this may be due to better diagnostic facilities, more accurate records of the disease or the increase in immigration to these countries.

The other clue which can help in the diagnosis of BSS and other hereditary thrombocytopenia from ITP is the presence of low platelet count in other family members (19, 20). ITP is an acquired disease and usually happens in one of the family. Therefore, the presence of family history of thrombocytopenia in ITP patients is a factor that can question the diagnosis. Accompanying the early onset bleeding at birth, mental retardation, cataracts, hearing loss, absent radius and renal failure with thrombocytopenia are other clues which we must think about hereditary thrombocytopenia in ITP patients (19). In our series, 6 groups of parents were relatives, 3 cases had family history of thrombocytopenia and one case had a bleeding event at birth and these findings helped to diagnose BSS.

In addition to clinical signs and symptoms, laboratory findings can also helpful in differentiating ITP and BSS. Prolonged bleeding time especially its inconsistency with platelet count (19), the presence of large platelets in peripheral blood smears and increased mean platelet volume (20) are laboratory findings which should be suspected to BSS in thrombocytopenic patients.

ITP is usually a self-limited disease and majority of patients will improve within 6 months. Furthermore 20-30% of affected children may develop chronic ITP (lasting for more than 12 months). Intravenous immunoglobulin (IVIG), corticosteroids or anti-D immunoglobulin is first line therapy and splenectomy, immunosuppressive therapy or rituximab are in the second line for these patients. In recent years, thrombopoietin (TPO) receptor agonists (romiplostim and eltrombopag) are used in refractory chronic ITP (21).

Lack of response to these therapies that are usually used for ITP treatment is one of the most important factors which should be suspected to diagnosis (19). In our series, the presence of consanguineous marriages in parents of 6 cases, family history low platelet in 3 cases and early onset bleeding at birth accompanied with laboratory findings and lack of proper response to treatment were clues which led to the diagnosis. In the past, there were also reports of BSS cases that had been misdiagnosed with chronic or refractory ITP and even treated as is for a long time period (16, 19, 22) but despite these reports, these two diseases have always been confused with each other.

In conclusion based on the very close similarities of BSS with ITP, this disease should always be considered in differential diagnosis of ITP especially in persistent and refractory ITP.

Acknowledgments

The author thanked of all patients and their parents for their kind cooperation.

Conflict of Interest: The author declare that she has no competing interests

References

1. López JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-soulier syndrome. Blood 1998; 91: 4397-418.
2. Lanza F. Bernard-soulier syndrome (hemorrhagiparous thrombocytic dystrophy). Orphanet J Rare Dis 2006; 1: 46
3. Osmanagaoglu M, Osmanagaoglu S, Bozkaya H. Bernard-Soulier syndrome in pregnancy: a case report. Internet J Gynecol Obstet 2005; 4. Available at: https://print.ispub.com/api/0/ispub-article/5208.
4. Kunishima S, Kamiya T, Saito H. Genetic abnormalities of Bernard-Soulier syndrome. Int J Hematol 2002; 76: 319-27.
5. Savoia A, PastoreA, De RoccoD, et al. Clinical and genetic aspects of Bernard-Soulier syndrome: searching for genotype/phenotype correlations. Haematologica 2011; 96: 417–23.
6. Toogeh G, Keyhani M, Sharifian R, Safae R, Emami A, Dalili H. A Study of bernard-soulier syndrome in Tehran, Iran. Arch Iran Med 2010; 13: 549-51.
7. Borhany M, Pahore Z, Qadr Z, et al. Bleeding disorders in the tribe: result of consanguineous in breeding. Orphanet J Rare Dis 2010; 5: 23.
8. Afrabiasi A, Artoni A, Karimi M, et al. Glanzmann thrombasthenia and Bernard–Soulier syndrome in south Iran. Clin Lab Haem 2005; 27: 324-7.
9. Geil JD, Yaish HM. Bernard-soulier syndrome. Available at: http://emedicine.medscape.com/article/954877-overview [Updated: 2018 Sep 13]. Accessed Nov 3, 2018.
10. University of Nottingham. Bernard soulier syndrome—clinical aspects. Available at: URL: https://www.nottingham.ac.uk/research/groups/structural-biology/research-projects/bss---clinical-aspects.aspx. Accessed Sep 10, 2018.
11. World Federation of Hemophilia, Bernard-soulier syndrome. Available at: URL: https://www.wfh.org/en/page.aspx?pid=657. Accessed Oct 1, 2018.
12. Hadjati S, Farsinejad A, Faranoush M, et al. Quantitative immunophenotyping of platelet surface glycoproteins among Iranian patients with bernard-soulier syndrome. Iran J Blood Cancer 2014; 7: 3-9.
13. Seligsohn U. Treatment of inherited platelet disorders. Haemophilia 2012; 18: 161-5.
14. Chitlur M, Rajpurkar M, Recht M, et al. Recognition and management of platelet-refractory bleeding in patients with Glanzmann’s thrombasthenia and other severe platelet function disorders. Int J Gen Med 2017; 10: 95-9.
15. Schulze H, Gaedicke G. Immune thrombocytopenia in children and adults: what’s the same, what’s different? Haematologica 2011; 96: 1739-41.
16. Okan V, Araz M, Camci C, et al. Bernard-Soulier syndrome in a Turkish family. Int J Clin Pract 2002; 56: 546-8.
17. Pham A, Wang J. Bernard-Soulier syndrome: an inherited platelet disorder. Arch Pathol Lab Med 2007; 131: 1834-6.
18. WFH Annual Global Survey 2017. Available at: http://www1.wfh.org/publications/files/pdf-1714.pdf. Accessed Dec 1, 2018.
19. Ahmed Wasfi L, Hassan Issa AR, Ahmad Awad Aljuhani Sh, Omar R. A case report of bernard-soulier syndrome in differential diagnosis of immune thrombocytopenic purpura. Int J Adv Res 2018; 6: 120-30.
20. Fiore M, Pillois X, Lorrain S, et al. A diagnostic approach that may help to discriminate inherited thrombocytopenia from chronic immune thrombocytopenia in adult patients. Platelets 2016; 27: 555-62.
21. Osman ME. Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist. Sudan J Paediatr 2012; 12: 60-4.
22. De Moerloose P, Vogel JJ, Clemetson KJ, et al. Bernard-Soulier syndrome in a Swiss family. Schweiz Med Wochenschr 1987; 117: 1817-21.